REAL SCIENCE. REAL POSSIBILITIES.Found naturally in every cell, NAD+ helps the body turn nutrients into usable energy and has become a major focus of metabolism and healthy-ageing research.
NAD+ sits at the centre of cellular energy and redox biology, which is why it attracts interest across fatigue, metabolism, recovery and healthy-ageing discussions. Human evidence is developing, but direct NAD+ administration should be kept separate from evidence for precursors such as NR and NMN.
These cards show what NAD+ is best known for and where the interest comes from. When you want the detail, open Research for the studies or Evidence for a quick view of how strong the support is.
The main reasons this compound attracts attention. The Research and Evidence sections give you the deeper scientific picture.
NAD+ is fundamental to the reactions cells use to transfer energy from nutrients into usable cellular energy.
Human and mechanistic research supports NAD+'s central biochemical role, while clinical benefits from raising or administering NAD+ depend on the intervention and population studied.
NAD biology is closely linked with glucose handling, mitochondrial function and broader metabolic pathways.
Clinical research across the NAD family has explored metabolic outcomes, but results from NR, NMN, NADH and direct NAD+ cannot be treated as interchangeable.
Energy, fatigue and recovery are among the most common reasons people discuss NAD+ in wellness settings.
Direct clinical evidence for broad fatigue or recovery benefits remains limited and subjective reports are mixed, including reports of both increased and reduced energy.
NAD+ also supports enzymes involved in cellular signalling, stress responses and maintenance processes.
These pathways provide a strong mechanistic rationale for research, but pathway activity should not be presented as proof of a specific clinical benefit.
Age-related changes in NAD metabolism have made the NAD system a major area of ageing research.
Human studies of NAD-boosting strategies show biochemical target engagement more consistently than they show broad improvements in healthspan or function.
NAD-related interventions are also being studied in defined clinical populations rather than only in general wellness settings.
Published human work includes disease-specific and pharmacokinetic studies, reinforcing that outcomes depend heavily on route, dose, formulation and population.
NAD+ is central to cellular redox and energy metabolism. Research spans direct NAD+ administration, NADH and precursors such as NR and NMN, but results from those interventions need to remain clearly separated.
NAD+ transfers electrons in core metabolic reactions that connect nutrients with cellular energy production.
The NAD+/NADH pair is a central part of cellular redox chemistry and is studied across many physiological systems.
NAD+-dependent enzymes link the coenzyme with stress responses, DNA-related processes and other cell-maintenance pathways.
Direct NAD+, NADH, NR and NMN are related biologically but differ in route, pharmacology and the human evidence available.
113 eligible studies: 33 human intervention studies and 80 rodent studies
Randomized clinical trials of NAD+ and NADH supplementation
Human intervention literature exists across NAD-related compounds, but direct NAD+ intervention evidence is much thinner than the broader NR/NMN literature.
This score reflects completed human outcome evidence. A registered or recruiting trial does not count until results are reported.
Short-term human data exist for related NAD-boosting approaches; parenteral NAD+ has much less outcomes evidence and sterile-compounding quality is a separate safety issue.
Rodent studies are numerous and frequently report metabolic, mitochondrial and inflammatory effects, but they remain preclinical.
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
NR, NMN, NAD+ and NADH are biologically related, but evidence for one should not automatically be attributed to another.
Evidence belongs to the intervention actually studied. NR, NMN, NADH and administered NAD+ are related, but results cannot be silently transferred between them.
Oral human intervention literature includes biochemical target engagement; functional outcomes remain heterogeneous.
Oral human trials report target engagement, with mixed or endpoint-specific clinical findings.
Open NMN profile →Direct parenteral NAD+ has far less eligible outcomes evidence than the broader precursor literature.
Some human trials exist, but NADH is a distinct intervention and should not be treated as direct NAD+ evidence.
The review covered the wider NAD-boosting field. Oral NR/NMN had clearer biochemical target engagement than direct IV/IM NAD+ had eligible clinical outcomes evidence.
2026 systematic review · PMID 41655607 ↗This review included NAD-related interventions across several clinical conditions, including NADH and precursor-related approaches; it does not make all NAD-family interventions interchangeable.
Systematic review · PMID 37971292 ↗FDA has warned that food-grade NAD+ is not suitable for sterile compounding without appropriate processing because of microbial/endotoxin contamination risk. FDA has received adverse-event reports after injectable NAD+ use consistent with excessive endotoxins.
Recurring themes from peptide and wellness communities, shown alongside what published research currently suggests.
Community discussion commonly frames NAD+ around energy, mental clarity, recovery and sleep. Reports are notably inconsistent, including people describing fatigue rather than increased energy. Evidence for NR or NMN must not be presented as direct evidence for administered NAD+.
Experiences can reveal recurring goals, perceived changes and practical questions that formal studies may not yet address. They can suggest what deserves investigation, but cannot isolate the effect of one compound from rehabilitation, time or other changes.
Human and preclinical research helps test whether an idea is biologically plausible, whether it appears in people and how confidently the result can be separated from chance, bias or other parts of recovery.
Insufficient for broad wellness claim
Mechanistic rationale exists
A popular theory, but subjective reports conflict and precursor evidence cannot be transferred directly to NAD+.
Insufficient
Mechanistic interest
Community-reported benefit; not established as a general clinical effect of NAD+ administration.
Insufficient
Not enough to establish benefit
Anecdotal signal only; some users instead report tiredness or altered energy.
Not established
Biological rationale / animal research
Mechanism and biomarker changes should not be presented as proof of extended human healthspan or lifespan.
Community reports can surface patterns worth exploring. Controlled human research is what tests whether those patterns are reliable, clinically meaningful and attributable toNAD+, while the available studies show how far that question has already been answered.
Compare published study protocols with the patterns people discuss in the community. The two are intentionally kept separate so an anecdotal routine is never mistaken for clinical guidance.
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
Direct NAD+ administration has some human research, but protocols vary substantially by indication and setting.
Commercial-clinic clients
Published study structure, shown as data — not a personal dosing schedule.
Retrospective real-world study; not an efficacy dosing standard.
180 adults with ischemic cardiomyopathy
Published study structure, shown as data — not a personal dosing schedule.
Disease-specific research protocol; not transferable to wellness use.
Human cohort
Published study structure, shown as data — not a personal dosing schedule.
Pharmacokinetic/metabolomic protocol.
Wellness clinics and online communities discuss a very wide range of IV protocols.
Single infusions, short multi-day courses and periodic infusions are all discussed.
Regular 'maintenance' infusions are marketed and discussed, but a general evidence-based maintenance interval has not been established.
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
NAD+ + NMN / NR
The summary above reflects the human or preclinical evidence currently represented on this profile.
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
A January 2026 FDA warning letter described an NAD+ compounded lot with excessive bacterial endotoxins after three patients developed symptoms and were directed to emergency care.
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
NAD+ is a biological coenzyme rather than a single authorised medicine category; claims and product status depend on formulation and route.
FDA has warned about use of food-grade NAD+ for sterile compounding.
FDA ↗Regulatory status depends on the specific product, claim and route; production should resolve this at product level.
Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.